Whalen Wealth Management Inc. Acquires Shares of 6,163 Neurocrine Biosciences, Inc. $NBIX

Whalen Wealth Management Inc. acquired a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,163 shares of the company’s stock, valued at approximately $1,039,000.

Other institutional investors have also added to or reduced their stakes in the company. Royal Bank of Canada raised its holdings in shares of Neurocrine Biosciences by 36.7% in the first quarter. Royal Bank of Canada now owns 82,810 shares of the company’s stock worth $9,158,000 after buying an additional 22,224 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Neurocrine Biosciences by 60.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,783 shares of the company’s stock worth $1,647,000 after acquiring an additional 5,577 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in Neurocrine Biosciences by 56.3% during the 1st quarter. NewEdge Advisors LLC now owns 7,630 shares of the company’s stock valued at $844,000 after acquiring an additional 2,747 shares during the period. Empowered Funds LLC purchased a new position in Neurocrine Biosciences during the 1st quarter valued at $1,333,000. Finally, Geneos Wealth Management Inc. grew its position in Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Stephen A. Sherwin sold 25,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $165.32, for a total transaction of $4,133,000.00. Following the completion of the sale, the director directly owned 15,860 shares in the company, valued at approximately $2,621,975.20. The trade was a 61.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Ingrid Delaet sold 4,367 shares of the business’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $181.02, for a total transaction of $790,514.34. Following the transaction, the insider owned 16,225 shares of the company’s stock, valued at $2,937,049.50. This represents a 21.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 127,636 shares of company stock worth $21,059,908. 4.60% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms recently commented on NBIX. Wall Street Zen downgraded shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Sunday, August 9th. Stifel Nicolaus boosted their price objective on shares of Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Weiss Ratings downgraded shares of Neurocrine Biosciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, August 11th. Morgan Stanley reduced their target price on shares of Neurocrine Biosciences from $196.00 to $182.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 13th. Finally, The Goldman Sachs Group started coverage on shares of Neurocrine Biosciences in a research note on Tuesday, June 2nd. They set a “buy” rating and a $213.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $200.86.

Neurocrine Biosciences Stock Up 0.3%

Shares of NBIX opened at $153.04 on Tuesday. The company has a 50 day moving average of $167.02 and a two-hundred day moving average of $149.06. Neurocrine Biosciences, Inc. has a twelve month low of $122.14 and a twelve month high of $186.12. The company has a market cap of $15.56 billion, a price-to-earnings ratio of 22.44, a price-to-earnings-growth ratio of 0.71 and a beta of 0.39.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Friday, July 31st. The company reported $2.85 EPS for the quarter, beating analysts’ consensus estimates of $1.65 by $1.20. The company had revenue of $959.00 million during the quarter, compared to analysts’ expectations of $891.16 million. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%.The firm’s revenue was up 39.5% compared to the same quarter last year. During the same period last year, the business posted $1.65 earnings per share. On average, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 7.25 EPS for the current year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.